News Author: Will Pass Publish date: October 11, 2018
New research suggests genomic characteristics of patients with myeloproliferative neoplasms (MPNs) can predict clinical outcomes.
Investigators def...
News Author: Will Pass Publish date: October 10, 2018
In blood cancers, there is a shift away from clinical and morphologic classification and toward genomic classification.
News Author: Will Pass Publish date: October 10, 2018
One patient fully recovered and a second improved but had speech and mobility problems.
News Author: Will Pass Publish date: October 8, 2018
The findings challenge the Choosing Wisely campaign of the American Society of Nephrology, which recommends against NSAIDs for high-risk patients.<...
News Author: Will Pass Publish date: October 8, 2018
Allopurinol doses of at least 300 mg/day reduced risk of stage-3 or higher chronic kidney disease.
News Author: Will Pass Publish date: October 7, 2018
The cost-effectiveness of tisagenlecleucel (Kymriah) depends on long-term clinical outcomes, which are presently unknown, according to investigator...
News Author: Will Pass Publish date: October 2, 2018
Antibiotics cause increased proteolytic activity in the large intestine that disrupts the gut barrier, increasing risk of chronic colitis.
News Author: Will Pass Publish date: October 1, 2018
The therapy could help stave off graft-versus-host disease in stem cell transplant patients.
News Author: Will Pass Publish date: October 1, 2018
The CAR gene was unintentionally introduced into a single leukemic B cell during T-cell manufacturing.
News Author: Will Pass Publish date: October 1, 2018
Older patients with untreated Hodgkin lymphoma (HL) can achieve significantly improved survival by adding brentuximab vedotin to their treatment befor...
News Author: Will Pass Publish date: September 28, 2018
The therapy could help stave off graft-versus-host disease in stem cell transplant patients.
News Author: Will Pass Publish date: September 28, 2018
Future epigenetic drugs could activate human endogenous retroviruses (HERVs) in cancer cells to enable immunotherapy, investigators su...
News Author: Will Pass Publish date: September 24, 2018
A woman with two distinct primary tumors caused by Lynch syndrome achieved complete regression of both after pembrolizumab therapy.
News Author: Will Pass Publish date: September 23, 2018
Adding Bv to standard chemotherapy improved survival over historical rates.
News Author: Will Pass Publish date: September 23, 2018
A combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus and the BRAF inhibitor vemurafenib appears safe for patients with ad...
